Alector (ALEC) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Apr, 2026Executive summary
The annual meeting is scheduled for June 17, 2026, to be held virtually, with voting on director elections, auditor ratification, and executive compensation approval.
The record date for voting is April 20, 2026, with 111,025,187 shares of common stock outstanding.
Proxy materials are primarily distributed electronically, with options for paper copies upon request.
Voting matters and shareholder proposals
Shareholders will vote on electing three Class II directors, ratifying Ernst & Young LLP as auditor for 2026, and an advisory say-on-pay vote for executive compensation.
The board recommends voting FOR all proposals.
Shareholder proposals for the 2027 meeting must be submitted by December 29, 2026, for proxy inclusion, or between February 12 and March 14, 2027, for other business or nominations.
Board of directors and corporate governance
The board consists of eight members, six of whom are independent under Nasdaq rules.
Directors are divided into three staggered classes, with annual elections for one class.
The board is led by an independent chairperson, Louis J. Lavigne, Jr.
Committees include Audit, Compensation, and Corporate Governance and Nominating, each with defined responsibilities and independent membership.
The board emphasizes diversity, regular risk oversight, and executive sessions of independent directors.
Latest events from Alector
- Virtual annual meeting to elect directors, ratify auditor, and vote on executive pay.ALEC
Proxy filing29 Apr 2026 - ABC platform delivers potent, safe brain-targeted therapies with strong clinical and market potential.ALEC
Corporate presentation26 Mar 2026 - Biotech firm seeks to raise up to $400M for neurodegenerative R&D via flexible securities offering.ALEC
Registration Filing12 Mar 2026 - ABC platform delivers potent brain-targeted therapies, with IND and phase 1 trials imminent.ALEC
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - Revenue and expenses declined in 2025, with a net loss of $142.9M and cash runway through 2027.ALEC
Q4 202525 Feb 2026 - Late-stage neurodegeneration programs progress with pivotal data and strong pharma partnerships.ALEC
H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference3 Feb 2026 - Lead FTD drug nears pivotal data as pipeline advances and GSK partnership drives commercialization.ALEC
Cantor Global Healthcare Conference 20253 Feb 2026 - ABC platform enables efficient brain delivery, advancing therapies for neurodegenerative diseases.ALEC
Status Update3 Feb 2026 - Late-stage neurodegeneration trials progress, strong $503M cash runway supports outlook.ALEC
Q2 20242 Feb 2026